Foulston Law Office Blog

Monday, February 3, 2014

Takeda Jury To Hear Claims Over Actos Destroyed Files

Great news for folks injured by Actos diabetes drug. As most people know the first federal Actos trial is set to start on Monday February 3rd. The jury has been picked and is ready to go into a marathon trial expected to last several weeks.

Takeda Pharmaceutical Co., the manufacturer of the type 2 diabetic drug, Actos, must let a jury hear claims that it intentionally destroyed files related its Actos diabetes drug. The federal judge overseeing the trial has made this ruling, to allow this evidence and jury instruction, known as a Spoliation of Evidence. The jury is allowed to infer that the destroyed documents were damaging to the company.

Takeda Allegedly Intentionally Destroyed Key Documents

U.S. District Judge Rebecca Doherty said, Takeda admitted they can’t find files compiled by 46 current and former employees involved with the development, marketing and sale of Actos, including those of two directors. Some files were deleted from company computers after executives warned employees to retain Actos-related material.

“The breadth of Takeda leadership whose files have been lost, deleted or destroyed is, in and of itself, disturbing,” Doherty wrote in a January 27 court filing.

Takeda Under Fire

Takeda, Asia’s largest drug maker, is preparing for the federal-court trial in Lafayette, Louisiana, about a month after it scrapped development of another diabetes drug when research linked it to liver damage.

To punish the company, the judge will let lawyers for an Actos user suing Takeda over his bladder cancer tell jurors about the document destruction at his trial. The judge stopped short of awarding the plaintiff a default judgment over his case, stating that was too severe of a punishment.

Takeda Downplayed Actos Bladder Cancer Concerns

Plaintiffs allege that Takeda researchers ignored or downplayed concerns about the drug’s cancer-causing potential before it went on sale in the U.S. and misled FDA regulators about its risks.

Actos Blockbuster Drug

Sales of Actos peaked in the year ended March 2011 at $4.5 billion and accounted for 27 percent of Takeda’s revenue at the time, according to Bloomberg.
Actos has generated more than $16 billion in sales since its 1999 release, according to court filings.

Federal Court MDL

The consolidated Actos cases in Louisiana are In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette). Allen’s case is Allen v. Takeda Pharmaceuticals North America Inc., 12-cv-00064, U.S. District Court, Western District of Louisiana (Lafayette).

Posted by Shezad Malik MD JD
February 1, 2014 11:31 AM




Foulston Law Office assists clients in the State of Kansas with personal injury claims, and clients nationwide with medical device and prescription drug claims.



© 2024 Foulston Law Office | Disclaimer
8100 E.22nd St. North, Building 1200, Wichita, KS 67226
| Phone: 316-686-4196 | 800-820-8166

Firm Profile | FAQs | Areas of Service

-
-